Sibylle H. Lob

Sibylle H. Lob

Auto-generated profile, based on publicly available information

Sibylle H. Lob

IHMA, 2122 Palmer Drive, Schaumburg, IL, 60173, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2018 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
JKJames A Karlowsky
James A Karlowsky
SLSibylle H Lob
Sibylle H Lob
KKKrystyna M Kazmierczak
Krystyna M Kazmierczak
SHStephen P Hawser
Stephen P Hawser
SMSophie Magnet
Sophie Magnet
DSDaniel F Sahm
Daniel F Sahm
Relebactam is an inhibitor of class A β-lactamases, including KPC β-lactamases, and class C β-lactamases, and is currently under clinical development in combination with imipenem. The objective of the current study was to evaluate the in vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens (Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) submitted by clinical laboratories in 17 European countries to the Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance programme in 2015. MICs were determined using the CLSI standard broth microdilution method and interpreted using EUCAST clinical breakpoints. Relebactam was tested at a fixed concentration of 4 mg/L in combination with doubling dilutions of imipenem. Imipenem/relebactam MICs were interpreted using breakpoints for imipenem. Rates of susceptibility to imipenem and imipenem/relebactam for isolates of P. aeruginosa (n = 1705), K. pneumoniae (n = 1591) and Enterobacter spp. (n = 772) were 72.0/94.7%, 88.7/94.8% and 95.6/96.8%, respectively. Relebactam restored imipenem susceptibility to 81.1%, 54.2% and 26.5% of imipenem-non-susceptible isolates of P. aeruginosa (n = 477), K. pneumoniae (n = 179) and Enterobacter spp. (n = 34). Most imipenem/relebactam-non-susceptible isolates carried MBLs, OXA-48 or GES carbapenemases. Relebactam did not increase the number of isolates of A. baumannii (n = 486) susceptible to imipenem. Relebactam restored susceptibility to imipenem for the majority of imipenem-non-susceptible isolates of P. aeruginosa and K. pneumoniae tested as well as some isolates of imipenem-non-susceptible Enterobacter spp. Based on our results, imipenem/relebactam appears to be a promising therapeutic option for treating patients with infections caused by antimicrobial-resistant Gram-negative bacilli.

26 January 2022 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
JKJames A. Karlowsky
James A. Karlowsky
SLSibylle H. Lob
Sibylle H. Lob
CDC. Andrew DeRyke
C. Andrew DeRyke
FSFakhar Siddiqui
Fakhar Siddiqui
KYKatherine Young
Katherine Young
DSDaniel F. Sahm
Daniel F. Sahm

1 December 2018 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Closed access
JKJames A. Karlowsky
James A. Karlowsky
SLSibylle H. Lob
Sibylle H. Lob
KYKatherine Young
Katherine Young
MMMary R. Motyl
Mary R. Motyl
DSDaniel F. Sahm
Daniel F. Sahm

1 June 2020 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
JKJames A. Karlowsky
James A. Karlowsky
SLSibylle H. Lob
Sibylle H. Lob
KKKrystyna M. Kazmierczak
Krystyna M. Kazmierczak
KYKatherine Young
Katherine Young
MMMary Motyl
Mary Motyl
DSDaniel F. Sahm
Daniel F. Sahm
Antimicrobial resistance including multidrug-resistance (MDR) is increasing especially among Gram-negative bacilli. New agents are needed to treat infections caused by these pathogens. For this report, the activity of imipenem-relebactam was assessed against Gram-negative bacilli from intraabdominal infections (IAIs) and urinary tract infections (UTIs) submitted to the SMART (Study for Monitoring Antimicrobial Resistance Trends) global surveillance program in the United States from 2015 to 2017. Broth microdilution MICs for imipenem-relebactam and comparators were determined by a central laboratory against isolates of non-Proteeae Enterobacteriaceae (NPE) and Pseudomonas aeruginosa. Imipenem-relebactam MICs were interpreted using United States Food and Drug Administration (FDA) breakpoints. 99.5% of NPE isolates collected from patients with IAIs (n = 3,633) and UTIs (n = 3,038) were susceptible to imipenem-relebactam, as were 77.9% of imipenem-nonsusceptible, 96.3% of KPC-positive, and 98.7% of MDR isolates from IAIs and UTIs combined. 96.7% of IAI isolates (n = 486) and 96.4% of UTI isolates (n = 360) of P. aeruginosa were susceptible to imipenem-relebactam, as were 85.0% of imipenem-nonsusceptible and 87.3% of MDR isolates from IAIs and UTIs combined. Percent susceptibility to imipenem-relebactam for cefepime-, ceftazidime-, and piperacillin-tazobactam-nonsusceptible isolates was 98.3-98.8% for NPE and 87.3-90.0% for P. aeruginosa. Imipenem-relebactam demonstrated potent in vitro activity against NPE and P. aeruginosa isolates from IAIs and UTIs, including against resistant subsets, and will provide important coverage for IAIs and UTIs caused by β-lactam-resistant, MDR, and KPC-positive Gram-negative bacilli.

1 July 2018 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
JKJames A. Karlowsky
James A. Karlowsky
SLSibylle H. Lob
Sibylle H. Lob
KKKrystyna M. Kazmierczak
Krystyna M. Kazmierczak
KYKatherine Young
Katherine Young
MMMary R. Motyl
Mary R. Motyl
DSDaniel F. Sahm
Daniel F. Sahm
Relebactam is a non-β-lactam, bicyclic diazabicyclooctane β-lactamase inhibitor of class A and class C β-lactamases, including Klebsiella pneumoniae carbapenemases (KPCs). It is in phase 3 clinical development in combination with imipenem/cilastatin. The in vitro activities of imipenem-relebactam, imipenem, and comparators were determined using the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method for isolates of Enterobacteriaceae ( n = 3,419) and Pseudomonas aeruginosa ( n = 896) collected in 2016 by 21 U.S. hospital laboratories participating in the SMART (Study for Monitoring Antimicrobial Resistance Trends) global surveillance program. Relebactam was tested at a fixed concentration of 4 μg/ml. Imipenem-relebactam MICs were interpreted using CLSI breakpoints for imipenem. Rates of susceptibility to imipenem-relebactam and imipenem for non- Proteeae Enterobacteriaceae ( n = 3,143) and P. aeruginosa were 99.1% (3,115/3,143) and 95.9% (3,013/3,143) and were 94.4% (846/896) and 74.7% (669/896), respectively. Relebactam restored imipenem susceptibility to 78.5% (102/130) of imipenem-nonsusceptible non- Proteeae Enterobacteriaceae and to 78.0% (177/227) of imipenem-nonsusceptible P. aeruginosa isolates. Susceptibility to imipenem-relebactam was 98.2% (444/452) and 82.2% (217/264) for multidrug-resistant (MDR) non- Proteeae Enterobacteriaceae and MDR P. aeruginosa , respectively. Given the ability of relebactam to restore susceptibility to imipenem in nonsusceptible isolates of both non- Proteeae Enterobacteriaceae and P. aeruginosa and to demonstrate potent activity against current MDR isolates of both non- Proteeae Enterobacteriaceae and P. aeruginosa , further development of imipenem-relebactam appears warranted.

17 May 2022 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
JKJames A. Karlowsky
James A. Karlowsky
SLSibylle H. Lob
Sibylle H. Lob
CDC. Andrew DeRyke
C. Andrew DeRyke
DHDavid W. Hilbert
David W. Hilbert
MWMichael T. Wong
Michael T. Wong
DSDaniel F. Sahm
Daniel F. Sahm
Ceftolozane-tazobactam (C/T), imipenem-relebactam (IMR), and ceftazidime-avibactam (CZA) were tested against 2,531 P. aeruginosa strains isolated from patients in the United States from 2018 to 2020 as part of the SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance program. MICs were determined by CLSI broth microdilution and interpreted using CLSI M100 (2021) breakpoints.